FLORHAM PARK, N.J. (CBSNewYork) — The Food and Drug Administration has just given approval for a New Jersey company to use immunotherapy to treat adults with the coronavirus.

Celularity, based in Florham Park, will begin clinical trials on as many as 86 patients with COVID-19.

READ MORE: Gen. Colin Powell, Former Secretary Of State, Dies At 84 Due To Complications From COVID-19

In the treatment, so-called natural killer cells from human placentas will be given to corona-infected patients.

READ MORE: COVID Vaccine Mandate Takes Effect For Workers At New Jersey Schools, Colleges, Universities And State Agencies

It’s believed those cells shield a fetus from the coronavirus and could also destroy the virus in sick adults.

MORE NEWS: FDA, CDC May Approve COVID Vaccine Booster Shots For Millions This Week

The treatment is currently tested against certain types of cancer.